Vcare PharmaTech Ranked in Tier 1 of "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" for Two Consecutive Years
Published Time:
2026-06-29 17:39
Source:
On June 26, the authoritative ranking of the "Top 100 Chinese Innovative Pharmaceutical Seed Enterprises 2026" (Seed 100 List) was officially released. Relying on its technological moat built by AI-driven original innovation, a complete independent R&D system, a tiered global innovation pipeline, marketed innovative drug achievements and comprehensive global patent portfolio layout, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) has once again been listed in Tier 1 of the ranking, marking its sixth consecutive year on the Seed 100 List.
Vcare PharmaTech has secured a spot on the Seed 100 List for six straight years since 2021. It entered Tier 1 for the first time in 2025 and retained this position this year. Its consistent listing and Tier 1 standing serve as high recognition of the company’s long-term dedication to developing innovative medicines and leading therapies, and fully validate its comprehensive strength and steady growth in technological innovation and translation, new drug research as well as clinical development.
AI Empowerment Fuels Differentiated Original Drug Design
Upholding independent incubation and original innovation, Vcare PharmaTech actively integrates cutting-edge technologies with new drug discovery, with a strategic focus on AI-enabled differentiated original molecular design. Artificial intelligence technology accelerates core R&D workflows including target identification, molecular design and candidate compound optimization, greatly boosting R&D efficiency and clinical success rates. This forward-looking strategy has built robust technological barriers across the entire innovative drug development cycle, and further consolidated the deeply collaborative industrial chain covering technology research, drug development and commercial manufacturing.
Accelerated Rollout of Innovation Pipeline; First Anti-Tumor Targeted Drug Granted Marketing Approval
Early June witnessed a landmark breakthrough in Vcare PharmaTech’s innovative drug development pipeline: VELMARTO® (Eratrectinib), the company’s self-developed Class 1 small-molecule targeted anti-tumor drug, obtained marketing approval from the NMPA. This milestone signals Vcare PharmaTech’s official transition from an R&D-focused biotech firm to an integrated enterprise covering both research and commercialization.
Meanwhile, the company’s innovation pipeline has delivered multiple key advances: one candidate drug has formally accepted NDA approval, several candidates are undergoing Phase II and Phase III clinical trials, and a batch of pre-clinical innovative drug programs are under continuous incubation. The tiered pipeline covers core therapeutic areas including oncology, cardiovascular and cerebrovascular diseases, as well as inflammatory and autoimmune disorders, forming a globally competitive product portfolio.
Address Unmet Clinical Needs via Differentiated R&D to Forge Global Competitiveness
Moving forward, Vcare PharmaTech will stay committed to its strategic mission of "addressing unmet clinical needs through differentiated innovation". The company will further expand its innovative drug pipeline, leverage the technical strengths of AI-powered original discovery, and speed up the research, translational development and commercial launch of more Class 1 innovative medicines. It aims to build a diversified innovative drug portfolio with solid technological barriers and outstanding clinical competitiveness across multiple disease areas, deliver superior treatment options for patients worldwide, and fuel high-quality growth of China’s pharmaceutical innovation sector.
About the Seed 100 List
The Seed 100 List selects enterprises representing the innovation potential of China’s pharmaceutical industry. Compiled by authoritative industrial media E Pharma Manager, the ranking adopts an evaluation framework centered on innovation foundation, innovation process and innovation output. Based on Clarivate’s Cortellis competitive intelligence, clinical trial data and Derwent Innovation patent database, evaluators analyze metrics including the number of granted patents, total patent citations, ongoing clinical trial programs, and approved/marketed new medicines to shortlist the top 100 innovative pharmaceutical enterprises.
Previous Page
Related News
26
2017
/
09
Jiangsu Vcare Organized an Emergency Response Training
On September 22, 2017, Vcare invited the teachers of Nanjing Science Education Center to teach company employees some emergency knowledge. There were more than 40 employees participated in the training. The main training contents included prevention for accidents, treatment for emergencies, emergency techniques for CPR on-site and first aid, work fatigue, prevention and improvement of common occupational diseases. Employees learned a lot from the training.
View Details
15
2017
/
09
Jiangsu Vcare’s New R&D Center and Headquarter are being constructed
Jiangsu Vcare Pharmaceutical Technology Co., Ltd. bought a 20 mu of land in Biomedical Valley, Nanjing High-tech Industrial Development Zone, Jiangbei New District on August 15, 2017. The area is equipped with metro line 3 and the subway S8. It is about 4 kilometers away from the Nanjing High-speed Railway North Station which is under construction. The surrounding environment is very beautiful and the traffic is very convenient. It is constructed as Vcare’s headquarter and drug research and development center and the center was put into use at the end of 2019.
View Details
31
2017
/
08
Jiangsu Vcare Held “Team Building Training” Activity
Jiangsu Vcare held “Team Building Training” activity in the town of Chaxi at the end of August. The activity was divided into several parts and each task is completed within specified time. Participants need to communicate and coordinate with team awareness.
View Details
31
2017
/
08
Jiangsu Vcare Held Ten Kilometers Run Activity
87 participants arrived at the main entrance of Xuanwu Lake to participate in a ten-kilometer running activity after warm-up at 7 o'clock on August 31. Six colleagues on a business trip in Hainan and seven colleagues on a business trip in Xi'an also actively participated in the running at the local. Everyone completed the ten-kilometer running after one hour and a half and was very happy to give a test to our physical fitness through the running.
View Details
23
2017
/
08
Jiangsu Vcare Was Honored as Jiangbei New Area Lingque Enterprise
In 2017, the list of “Lingque” enterprises in Jiangbei New District of Nanjing was announced and Jiangsu Vcare Pharmaceutical Technology Co., Ltd. was successfully selected into the list. “Lingque” enterprises project aim to select a group of innovative SMEs with high growth in Jiangbei district and provide the selected enterprises with one-stop support such as equity investment, emergency turnover, loan interest subsidy, R&D subsidies, and etc.. To be successfully selected into the “Lingque” enterprises program is an inspiration to the company. Vcare keep integrating various resources to quickly become bigger and stronger to contribute to the development of Jiangbei New Area.
View Details
15
2017
/
06
Jiangsu Vcare and Yangzhou Princechem Acquired Boya Chemical Company
The signing ceremony of Jiangsu Vcare Pharmaceutical Technology Co., Ltd. and Yangzhou Princechem Co., Ltd. acquiring Boya Chemical (Nantong) Co., Ltd. was held in the conference room of Jiangsu Vcare recently. Boya Chemical (Nantong) Co., Ltd. is located in Yangkou Chemical Industrial Park, Rudong Coastal Economic Development Zone, Jiangsu Province. The company covers an area of 70 acres and is a Hong Kong-owned enterprise. The goal of this acquisition is to build Boya Chemical into a raw material drug manufacturer that meets the standards of China, the United States and the European Union. After renovation, Boya Chemical will be a chemical raw materials production base of Yatai Group and solve the bottleneck problem of Vcare's raw material drug R&D and production. It’s believed that the acquisition will make a significant contribution to Vcare’s production and sales of intermediates and APIs.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn